Our Products and Technologies IMBIO®
IMB’s Lead Product Candidate, Occlusin® 500 Embolization Microspheres (Occlusin® 500), is a “first in class” biodegradable embolic agent for the treatment of malignant and non-malignant vascularised tumors. Examples of vascularised tumors include heptocellular carcinoma (HCC; liver cancer), renal cell carcinoma (RCC; kidney cancer), and uterine fibroids.
Occlusin® 500 is a medical device cleared by the FDA for treatment of hypervascularized tumors. An embolic agent blocks the blood supply to a target tissue. In contrast to currently marketed embolic agents that are permanent implants, Occlusin® 500 has the unique advantage of biodegradability. Permanent implants remain in the body while biodegradable Occlusin® 500 is gradually removed from the body leading to reopening of the blocked blood vessel (recanalization). Further, Occlusin® 500 remains localized to the site of administration. Since Occlusin® 500 is classified as a medical device rather than a drug or biologic product, the regulatory requirements are greatly reduced, which translates into lower development costs and a quicker time to market.